Most people taking popular drugs like Ozempic and Wegovy to lose weight have shed significant pounds. But obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust ...

Antag Therapeutics thinks its glucose dependent insulinotropic polypeptide receptor (GIPR) antagonist could carve out a space ...

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

Pfizer's Chris Boshoff outlines plans to prioritize high-return projects, with a focus on obesity, Oncology, and oral GLP-1 ...

Researchers have developed and are testing a small, implanted gastric balloon that people can inflate or deflate to feel full ...

Is It Better To Shower In The Morning Or At Night? Well, It Depends.

Brand companies who own GLP-1 products have been pushing the Food and Drug Administration (FDA) to limit their compounding. On August 28, 2024, ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1 receptor agonist use is associated with benefits in a number of different disease and may help treat patients with lupus nephritis.

Although it looks like there may be some mounting pessimism surrounding Viking Therapeutics stock recently, its shares are ...

About one-third of U.S. adults without diabetes who are eligible for weight loss treatment with glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/glucose-dependent insulinotropic polypeptide ...

In a new guidance statement, the American Diabetes Association advises against the use of unapproved products, warning of ...